Hørsholm, Denmark, 27 March 2023 - On 3 March 2023, the Board of Directors of Expres2ion Biotech Holding AB ("ExpreS2ion" or the "Company") resolved, conditional upon approval from the extraordinary general meeting, to carry out a new issue of units consisting of shares and warrants of series TO8 ("Units") with preferential rights for the Company's existing shareholders (the "Rights Issue"). On 23 March 2023, the extraordinary general meeting approved the Board of Directors' resolution to carry out the Rights Issue.

Hørsholm, Denmark, 16 March 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in March. Both sponsored research analysts commented on the recently announced rights issue and MucoVax collaboration. Analysguiden reduced its price target to SEK 12 per share, primarily a result of dilution from the rights issue and updates to its estimates for ABNCoV2, the COVID-19 vaccine candidate.

N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail.

Shareholders of ExpreS[2]ion Biotech Holding AB are hereby invited to an Extraordinary General Meeting on 23 March 2023 at 10:00 CET at Mindpark, Bredgatan 11, 252 25 Helsingborg, Sweden. The entrance to the meeting and registration will open at 09:30 CET.

Hørsholm, Denmark, March 3, 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that the MucoVax consortium has been awarded an Innovation Fund Denmark (IFD) Grand Solutions grant for the development of new platforms for universal mucosal vaccines in a 5-year research project in a collaboration between ExpreS2ion and University of Copenhagen. The award funding covers 71% of the research project and amounts to 29 MDKK (approx. 43 MSEK), of which ExpreS[2]ion directly is funded with 9.6 MDKK (approx. 14 MSEK).